Evidence map›Paper›PMID 30134551›Full record

ArticleGenes2018

In Silico Analysis of Hepatitis B Virus Occult Associated Mutations in Botswana Using a Novel Algorithm.

Motswedi Anderson, Wonderful T Choga, Sikhulile Moyo, Trevor Graham Bell, Tshepiso Mbangiwa, Bonolo B Phinius, Lynette Bhebhe, Theresa K Sebunya, Joseph Makhema, Richard Marlink and 5 more

Open access · goldAbstract read
In one paragraph

Article in Genes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Motswedi AndersonBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. motswedi.anderson@gmail.com.
Wonderful T ChogaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. wtchoga@gmail.com.
Sikhulile MoyoBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. smoyo@bhp.org.bw.ORCID 0000-0003-3821-4592
Trevor Graham BellHepatitis Virus Diversity Research Unit (HVDRU), Faculty of Health Sciences, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg 2050, South Africa. trevorgrahambell@gmail.com.ORCID 0000-0003-2630-7513
Tshepiso MbangiwaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. mbangiwat@gmail.com.
Bonolo B PhiniusBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. bphinius@gmail.com.
Lynette BhebheBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. lynnettebhebhe@gmail.com.
Theresa K SebunyaFaculty of Science, Department of Biological Sciences, University of Botswana, Gaborone, Botswana. sebunyat@gmail.com.
Joseph MakhemaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. jmakhema@bhp.org.bw.
Richard MarlinkBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. rmarlink@globalhealth.rutgers.edu.
Anna KramvisHepatitis Virus Diversity Research Unit (HVDRU), Faculty of Health Sciences, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg 2050, South Africa. anna.kramvis@wits.ac.za.ORCID 0000-0001-6006-3765
Max EssexBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. messex@hsph.harvard.edu.
Rosemary M MusondaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. rmusonda@bhp.org.bw.
Jason T BlackardCollege of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA. blackajt@ucmail.uc.edu.ORCID 0000-0003-2876-3811
Simani GaseitsiweBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. sgaseitsiwe@bhp.org.bw.
Botswana Harvard AIDS Institute Partnership · BWHarvard University · USUniversity of Botswana · BWUniversity of the Witwatersrand · ZARutgers, The State University of New Jersey · USUniversity of Cincinnati Medical Center · US

Funding

Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4M
Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
FIC NIH HHS D43 TW009610FIC NIH HHS D43 TW010543NIDDK NIH HHS P30 DK078392
6 · The paper itself

Abstract

Occult hepatitis B infections (OBI) represent a reservoir of undiagnosed and untreated hepatitis B virus (HBV), hence the need to identify mutations that lead to this phenotype. Functionally characterizing these mutations by in vitro studies is time-consuming and expensive. To bridge this gap, in silico approaches, which predict the effect of amino acid (aa) variants on HBV protein function, are necessary. We developed an algorithm for determining the relevance of OBI-associated mutations using in silico approaches. A 3 kb fragment of subgenotypes A1 and D3 from 24 chronic HBV-infected (CHB) and 24 OBI participants was analyzed. To develop and validate the algorithm, the effects of 68 previously characterized occult-associated mutations were determined using three computational tools: PolyPhen2, SNAP2, and PROVEAN. The percentage of deleterious mutations (with impact on protein function) predicted were 52 (76.5%) by PolyPhen2, 55 (80.9%) by SNAP2, and 65 (95.6%) by PROVEAN. At least two tools correctly predicted 59 (86.8%) mutations as deleterious. To identify OBI-associated mutations exclusive to Botswana, study sequences were compared to CHB sequences from GenBank. Of the 43 OBI-associated mutations identified, 26 (60.5%) were predicted by at least two tools to have an impact on protein function. To our knowledge, this is the first study to use in silico approaches to determine the impact of OBI-associated mutations, thereby identifying potential candidates for functional analysis to facilitate mechanistic studies of the OBI phenotype.

Indexed as

AfricaBotswanaHBVHepatitis Bin-silico analysismutationsoccult hepatitis B virus

Identifiers

PMID30134551
PMCPMC6162659
OpenAlexW2888010527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.